Molecular status 36 months after TKI discontinuation in CML is
highly predictive for subsequent loss of MMR-final report from
AFTER-SKI

J 2021

Molecular status 36 months after TKI discontinuation in CML is highly predictive for subsequent loss of MMR-final report from AFTER-SKI

RICHTER, J., A. LUBKING, S. SODERLUND, K. LOTFI, B. MARKEVARN et. al.

Basic information

Original name

Molecular status 36 months after TKI discontinuation in CML is highly predictive for subsequent loss of MMR-final report from AFTER-SKI

Authors

RICHTER, J. (guarantor), A. LUBKING, S. SODERLUND, K. LOTFI, B. MARKEVARN, A. SJALANDER, L. STENKE, S. DENEBERG, E. AHLSTRAND, K. MYHR-ERIKSSON, P. PANAYIOTIDIS, T. GEDDE-DAHL, Daniela ŽÁČKOVÁ (203 Czech Republic, belonging to the institution), Jiří MAYER (203 Czech Republic, belonging to the institution), U. OLSSON-STROMBERG, F. X. MAHON, S. SAUSSELE, H. HJORTH-HANSEN and P. KOSKENVESA

Edition

Leukemia, London, Nature Publishing Group, 2021, 0887-6924

Other information

Language

English

Type of outcome

Článek v odborném periodiku

Field of Study

30205 Hematology

Country of publisher

United Kingdom of Great Britain and Northern Ireland

Confidentiality degree

není předmětem státního či obchodního tajemství

References:

URL

Impact factor

Impact factor: 12.883

RIV identification code

RIV/00216224:14110/21:00121497

Organization unit

Faculty of Medicine

DOI

http://dx.doi.org/10.1038/s41375-021-01173-w

UT WoS

000618175800004

Keywords in English

TKI discontinuation; CML; MMR-final report; AFTER-SKI

Abstract

V originále

Discontinuation of tyrosine kinase inhibitor (TKI) treatment for chronic phase (CP) CML patients with a deep molecular response (DMR) has entered standard practice. This is based on numerous clinical studies showing that ~50% of patients with DMR can stop TKI treatment without imminent disease relapse. However, in most of these trials long-term follow-up has been limited.

Citovat

RICHTER, J., A. LUBKING, S. SODERLUND, K. LOTFI, B. MARKEVARN, A. SJALANDER, L. STENKE, S. DENEBERG, E. AHLSTRAND, K. MYHR-ERIKSSON, P. PANAYIOTIDIS, T. GEDDE-DAHL, Daniela ŽÁČKOVÁ, Jiří MAYER, U. OLSSON-STROMBERG, F. X. MAHON, S. SAUSSELE, H. HJORTH-HANSEN and P. KOSKENVESA. Molecular status 36 months after TKI discontinuation in CML is highly predictive for subsequent loss of MMR-final report from AFTER-SKI. Leukemia. London: Nature Publishing Group, 2021, vol. 35, No 8, p. 2416-2418. ISSN 0887-6924. Available from: https://dx.doi.org/10.1038/s41375-021-01173-w.

@article{1764396,
   author = {Richter, J. and Lubking, A. and Soderlund, S. and Lotfi, K. and Markevarn, B. and Sjalander, A. and Stenke, L. and Deneberg, S. and Ahlstrand, E. and MyhrandEriksson, K. and Panayiotidis, P. and GeddeandDahl, T. and Žáčková, Daniela and Mayer, Jiří and OlssonandStromberg, U. and Mahon, F. X. and Saussele, S. and HjorthandHansen, H. and Koskenvesa, P.},
   article_location = {London},
   article_number = {8},
   doi = {http://dx.doi.org/10.1038/s41375-021-01173-w},
   keywords = {TKI discontinuation; CML; MMR-final report; AFTER-SKI},
   language = {eng},
   issn = {0887-6924},
   journal = {Leukemia},
   title = {Molecular status 36 months after TKI discontinuation in CML is highly predictive for subsequent loss of MMR-final report from AFTER-SKI},
   url = {https://www.nature.com/articles/s41375-021-01173-w.pdf},
   volume = {35},
   year = {2021}
}

TY  - JOUR
ID  - 1764396
AU  - Richter, J. - Lubking, A. - Soderlund, S. - Lotfi, K. - Markevarn, B. - Sjalander, A. - Stenke, L. - Deneberg, S. - Ahlstrand, E. - Myhr-Eriksson, K. - Panayiotidis, P. - Gedde-Dahl, T. - Žáčková, Daniela - Mayer, Jiří - Olsson-Stromberg, U. - Mahon, F. X. - Saussele, S. - Hjorth-Hansen, H. - Koskenvesa, P.
PY  - 2021
TI  - Molecular status 36 months after TKI discontinuation in CML is highly predictive for subsequent loss of MMR-final report from AFTER-SKI
JF  - Leukemia
VL  - 35
IS  - 8
SP  - 2416-2418
EP  - 2416-2418
PB  - Nature Publishing Group
SN  - 08876924
KW  - TKI discontinuation
KW  - CML
KW  - MMR-final report
KW  - AFTER-SKI
UR  - https://www.nature.com/articles/s41375-021-01173-w.pdf
N2  - Discontinuation of tyrosine kinase inhibitor (TKI) treatment for chronic phase (CP) CML patients with a deep molecular response (DMR) has entered standard practice. This is based on numerous clinical studies showing that ~50% of patients with DMR can stop TKI treatment without imminent disease relapse. However, in most of these trials long-term follow-up has been limited.
ER  -

RICHTER, J., A. LUBKING, S. SODERLUND, K. LOTFI, B. MARKEVARN, A. SJALANDER, L. STENKE, S. DENEBERG, E. AHLSTRAND, K. MYHR-ERIKSSON, P. PANAYIOTIDIS, T. GEDDE-DAHL, Daniela ŽÁČKOVÁ, Jiří MAYER, U. OLSSON-STROMBERG, F. X. MAHON, S. SAUSSELE, H. HJORTH-HANSEN and P. KOSKENVESA. Molecular status 36 months after TKI discontinuation in CML is highly predictive for subsequent loss of MMR-final report from AFTER-SKI. \textit{Leukemia}. London: Nature Publishing Group, 2021, vol.~35, No~8, p.~2416-2418. ISSN~0887-6924. Available from: https://dx.doi.org/10.1038/s41375-021-01173-w.

Detailed Information on Publication Record